ABVX

Abivax SA - ADR

86.59

USD

-2.47

-2.77%

Oct 30, 15:59 UTC -4

Closed

After-Market

86.58

-0.01

-0.02%

Abivax SA - ADR (ABVX) Earnings

ABVX Earnings Reports

Positive Surprise Ratio

ABVX beat 2 of 7 last estimates.

29%

Next Report

Date of Next Report

Dec 14, 2026

Estimate for Q3 26 (Revenue/ EPS)

Implied change from Q2 26 (Revenue/ EPS)

Implied change from Q3 25 (Revenue/ EPS)

Abivax SA - ADR earnings per share and revenue

On Sep 21, 2026, ABVX reported earnings of -2.09 USD per share (EPS) for Q2 26, missing the estimate of -1.82 USD, resulting in a -14.47% surprise. Revenue reached 2.54 million, compared to an expected 2.55 million, with a -0.20% difference. The market reacted with a -4.99% price change (close before vs. close after earnings).

Looking ahead to Q3 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Ligand Pharmaceuticals Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$2.42

Actual

$2.67

Surprise

+9.91%

AstraZeneca PLC

Report Date

Oct 30, 2026 For Q3 26

Estimate

$2.66

Actual

$2.79

Surprise

+4.56%

Gilead Sciences Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$2.24

Actual

$2.54

Surprise

+13.66%

Bristol-Myers Squibb Co.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.20

Actual

$1.35

Surprise

+11.66%

Regeneron Pharmaceuticals Inc

Report Date

Oct 30, 2026 For Q3 26

Estimate

$16.47

Actual

$20.07

Surprise

+21.79%

Illumina Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.38

Actual

$1.44

Surprise

+4.18%

Alnylam Pharmaceuticals, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.65

Actual

$16.26

Surprise

+885.34%

Exelixis Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.81

Actual

$0.94

Surprise

+15.64%

Kymera Therapeutics, Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$1.29

Actual

-$1.32

Surprise

-2.17%

NovoCure Limited Ordinary Shares

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.24

Actual

-$0.09

Surprise

+63.88%

FAQ

What were Abivax SA - ADR's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Abivax SA - ADR reported EPS of -$2.09, missing estimates by -14.47%, and revenue of $2.54M, -0.2% below expectations.

How did the market react to Abivax SA - ADR's Q2 2026 earnings?

The stock price moved down -4.99%, changed from $103.45 before the earnings release to $98.29 the day after.

When is Abivax SA - ADR expected to report next?

The next earning report is scheduled for Dec 14, 2026.

What are the forecasts for Abivax SA - ADR's next earnings report?

Based on -- analysts, Abivax SA - ADR is expected to report EPS of -- and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.